Non-profit
Forbes highlights its “30 Under 30" list who are beginning to make their mark in the biopharma and healthcare industries.
At the Seraph Research Institute, scientists presented new research at the 2021 ASGCT that shows promise in treating HIV.
According to the Centers for Disease Control and Prevention, more than 35,000 Americans perish each year from antibiotic-resistant infections, and estimates have AMR claiming the lives of as many as 10 million globally by 2050.
The Prostate Cancer Foundation has been an early accelerator of research that is now coming to fruition, including the early research into PSMA and the discovery that two FDA-approved PARP inhibitors, olaparib (Lynparza) and rucaparib (Rubraca) could work against mutant genes in prostate cancer.
While the space is just beginning to emerge, therapies for long-haul COVID-19 patients are still very much an unmet need.
On the other hand, when dealing with a novel coronavirus, a certain amount of speed and urgency is necessary. Professor Chris Molloy, Chief Executive Officer of the U.K,’s Medicines Discovery Catapult, told BioSpace that real-time data should be considered, with a different lens applied.
While companies around the globe reduce staff amidst economic upheaval, there’s at least one industry on the rise - life sciences. Here’s who’s breaking ground on expansion projects.
Draper, a not-for-profit research and development organization, is speeding the process with new tools designed specifically to produce cell therapies at scale.
Novartis plans to make the drugs available to government, non-governmental organizations (NGOs) and other institutional customers in up to 79 countries at no profit.
The Bill & Melinda Gates Foundation supports international collaboration to expand global access to life-saving vaccines
PRESS RELEASES